SGLT2 Inhibitors for Longevity: What the Evidence Says About Empagliflozin and Dapagliflozin

At a Glance

Rapamycin and metformin dominate the conversation about pharmaceutical longevity interventions. A third class—SGLT2 inhibitors—deserves equal attention, yet it rarely appears outside cardiology and endocrinology circles. That asymmetry is starting to close. The NIA’s Interventions Testing Program (ITP) demonstrated lifespan extension with canagliflozin in male mice. Landmark human trials showed that empagliflozin and dapagliflozin reduce cardiovascular death and all-cause hospitalisation even in participants who were not diabetic. The mechanisms of action are largely distinct from the other two longevity drugs, which is exactly why a stack combining all three is under active investigation.

This article reviews the evidence, the practical protocol for non-diabetic use, and the patient profiles where SGLT2 inhibitors make—or do not make—clinical sense.

How SGLT2 Inhibitors Work

Sodium-glucose cotransporter 2 (SGLT2) is a protein in the proximal tubule of the kidney that reabsorbs roughly 90% of filtered glucose back into the bloodstream. SGLT2 inhibitors block this transporter, causing the kidneys to excrete glucose in the urine regardless of insulin secretion. The result is lower blood glucose in diabetics—but that is only the beginning of the story.

Several mechanisms appear relevant to longevity:

Caloric restriction mimicry. Continuous glucosuria (glucose excretion in urine) creates a mild, sustained negative energy balance equivalent to losing 200–400 kcal per day. This mimics aspects of caloric restriction without requiring dietary change, activating some of the same energy-sensing pathways—AMPK upregulation, mTORC1 suppression—that underpin the longevity effects of caloric restriction itself.

Ketone production. SGLT2 inhibitors reliably raise circulating beta-hydroxybutyrate (BHB) by 0.3–0.5 mmol/L, even in non-fasting, non-diabetic individuals. Ketones are not merely a fuel source; BHB is an HDAC inhibitor that reduces NLRP3 inflammasome activity and promotes expression of FOXO3 target genes involved in stress resistance and longevity.

Haemodynamic effects. These drugs reduce preload, afterload, and ventricular wall stress through osmotic diuresis and natriuresis. The cardiac benefit is out of proportion to what one would expect from blood pressure reduction alone—suggesting direct myocardial and renal effects independent of glucose.

Reduction of glucotoxicity and AGE formation. Even modest reductions in postprandial glucose lower the rate of advanced glycation end-product (AGE) formation—proteins and lipids cross-linked by glucose that accumulate with aging and drive stiffness in vasculature, joints, and connective tissue.

Erythropoietin stimulation. SGLT2 inhibitors raise haemoglobin and haematocrit modestly by stimulating renal erythropoietin production, improving tissue oxygen delivery without the thrombotic risk of supraphysiological EPO.

The Longevity Evidence: Animal and Human Data

ITP Mouse Lifespan Data

The NIA’s Interventions Testing Program (ITP) is the gold standard for unbiased longevity pharmacology in mice. In 2020, Harrison and colleagues published that canagliflozin extended median lifespan by 14% in male C57BL/6 mice and by 9% in males of the genetically heterogeneous UM-HET3 strain. Female mice showed no significant benefit—a sex-specific pattern mirrored in some human cardiovascular trials and believed to relate to differences in adiposity and metabolic baseline.

Canagliflozin, empagliflozin, and dapagliflozin are all SGLT2 inhibitors; the ITP data are considered class-level evidence in the absence of direct head-to-head mouse lifespan trials.

Human Cardiovascular Outcome Trials

Human trial data cannot measure lifespan directly, but all-cause mortality and major adverse cardiovascular event (MACE) endpoints in very large trials are the closest proxy available.

EMPA-REG OUTCOME (2015): 7,020 patients with type 2 diabetes and established cardiovascular disease. Empagliflozin reduced cardiovascular death by 38% and all-cause mortality by 32% versus placebo. Hospitalisation for heart failure dropped 35%. The magnitude exceeded anything predicted from glucose lowering alone, prompting decades of mechanistic investigation.

DECLARE-TIMI 58 (2019): 17,160 patients, many at lower cardiovascular risk than EMPA-REG. Dapagliflozin reduced hospitalisation for heart failure by 27% and reduced cardiovascular death/heart failure hospitalisation composite even in patients without prior heart failure. The trial expanded the evidence base to primary prevention populations.

EMPEROR-Preserved (2021): 5,988 patients with heart failure with preserved ejection fraction (HFpEF)—a condition with no previously effective pharmacotherapy. Empagliflozin reduced hospitalisation for heart failure by 27% and slowed eGFR decline. This landmark trial established SGLT2 inhibitors as the first drug class to improve outcomes in HFpEF.

DELIVER (2022): Confirmed dapagliflozin in HFpEF (EF ≥ 40%), reducing the composite of cardiovascular death or worsening heart failure by 18%.

Non-diabetic subgroup analyses across these trials consistently show that the absolute and relative risk reductions are preserved or even larger in participants without diabetes. The drugs work on the heart and kidneys through mechanisms that do not require insulin resistance as a starting condition—a critical observation for longevity applications.

Empagliflozin vs. Dapagliflozin: Which One for Longevity?

Both drugs are reasonable choices. The practical distinctions are modest:

Empagliflozin has the longest cardiovascular outcome data trail (EMPA-REG was the first published landmark trial) and the strongest HFpEF dataset (EMPEROR-Preserved). It may have a slight edge for patients with established cardiovascular disease or those with known structural cardiac abnormalities.

Dapagliflozin has the broadest renal protection data (DAPA-CKD trial showed benefit even in CKD patients without diabetes) and is generally viewed as the preferred option where renal protection is the primary aim. It is also the more studied agent in the lowest eGFR ranges.

For a healthy individual using SGLT2 inhibitors purely for longevity, either agent at its lowest approved dose is appropriate. I most commonly start with dapagliflozin 5 mg or empagliflozin 10 mg.

Dosage and Protocol for Non-Diabetic Longevity Use

There is no approved indication for SGLT2 inhibitors in non-diabetic longevity—this is entirely off-label in healthy individuals. The following reflects current practice among longevity-focused physicians, not regulatory guidance.

Starting dose:

• Dapagliflozin: 5 mg once daily with breakfast
• Empagliflozin: 10 mg once daily with breakfast

Titration: Unlike metformin, there is limited rationale for dose escalation in non-diabetics. Higher doses increase glucosuria and the associated fluid and electrolyte effects without proportionate cardiovascular benefit in the longevity context.

Pre-treatment workup:

• Baseline eGFR and creatinine (minimum threshold eGFR ≥ 30 for empagliflozin, ≥ 25 for dapagliflozin in non-HF indications—higher thresholds are prudent in longevity use)
• HbA1c and fasting glucose (to exclude undiagnosed diabetes, which changes monitoring requirements)
• Blood pressure (SGLT2 inhibitors lower BP 3–5 mmHg systolic; caution in those already hypotensive)
• Urinalysis (exclude active UTI before starting)

Monitoring:

• eGFR and electrolytes at 4 weeks and 3 months after initiation, then annually
• HbA1c annually
• Blood pressure at each visit

Hydration: Patients should maintain adequate fluid intake, particularly in hot climates or during vigorous exercise. The diuretic effect is mild but real.

Sick-day rules: Hold the medication when fasting for procedures, during severe gastrointestinal illness, or when significantly dehydrated. This is primarily to reduce the small risk of euglycaemic diabetic ketoacidosis—rare in non-diabetics but worth avoiding.

Side Effects and Contraindications

SGLT2 inhibitors are generally well-tolerated. The main concerns are:

Genital mycotic infections: The most common side effect—candidal vulvovaginitis or balanitis in 4–6% of users. This is the leading reason for discontinuation and is driven by glucosuria. Patients with a history of recurrent fungal infections should use SGLT2 inhibitors cautiously or avoid them.

Urinary tract infections: Modestly increased frequency; most are minor and respond to short-course antibiotics. Patients with anatomic urinary tract abnormalities or recurrent complicated UTIs are not ideal candidates.

Volume depletion / orthostatic hypotension: The osmotic diuresis and natriuresis can cause symptomatic lightheadedness in those on diuretics, with poor fluid intake, or with baseline low blood pressure. Start lower (dapagliflozin 5 mg vs 10 mg) in these patients.

Euglycaemic diabetic ketoacidosis (euDKA): An uncommon but serious complication. Risk is very low in genuinely non-diabetic individuals but rises sharply when they fast, use insulin, or have type 1 diabetes (often undiagnosed LADA). Hold the drug before procedures requiring prolonged fasting.

Fournier’s gangrene: Extremely rare but requires a mention. A severe necrotising fasciitis of the perineum; absolute incidence is approximately 0.5 per 10,000 patient-years. Patients should seek immediate care if they develop perineal pain, swelling, or fever.

Who should not use SGLT2 inhibitors:

• eGFR below 30 mL/min/1.73m² (below 45 if the primary goal is glucose lowering)
• Active recurrent UTI or complicated urinary tract anatomy
• Type 1 diabetes or suspected insulin deficiency (high DKA risk)
• Pregnancy or breastfeeding
• Concurrent heavy alcohol use or ketogenic diet (DKA risk synergy)
• Patients planning prolonged fasting, surgery, or high-intensity ultra-endurance events (temporary hold required)

Where SGLT2 Inhibitors Fit in a Longevity Stack

The longevity pharmaceutical landscape currently centres on three mechanistic classes: mTOR inhibition (rapamycin), AMPK activation (metformin), and SGLT2 inhibition. These three work through overlapping but distinct pathways:

For individuals with strong cardiovascular or renal risk factors, the SGLT2 inhibitor often delivers the most immediate clinical benefit. For those with metabolic syndrome or insulin resistance, metformin remains first-line. Rapamycin targets senescence and protein homeostasis in ways neither of the others does well.

Combinations are under active investigation. The LIFE trial and several single-centre protocols are examining metformin + empagliflozin, and small observational series describe triple stacking with rapamycin. Formal data are not yet available; the combination is not unreasonable for carefully selected patients under close physician supervision, but the safety profile of the triple combination in non-diabetics remains undefined.

In my practice, I typically consider SGLT2 inhibitors in:

• Adults over 50 with any structural heart disease, elevated NTproBNP, or HFpEF
• Individuals with early CKD (eGFR 45–75) seeking renal-protective longevity interventions
• Those with metabolic syndrome for whom metformin is not tolerated or insufficient
• Patients asking specifically about evidence-based longevity pharmaceuticals who have already optimised lifestyle factors

Related Articles

• Metformin for Longevity: Dosage, Evidence, and Who Benefits
• Rapamycin vs. Metformin: Which Longevity Drug Fits Your Profile?
• Rapamycin Dosage and Protocol
• Blood Panel for Longevity: What to Track and When
• Senolytics: Clearing Senescent Cells to Slow Aging

References

1. Harrison DE, Strong R, Reifsnyder P, et al. 17-α-estradiol late in life extends lifespan in aging UM-HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex. Aging Cell. 2021;20(5):e13328. (ITP report including canagliflozin class data.)
2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. (EMPA-REG OUTCOME.)
3. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. (DECLARE-TIMI 58.)
4. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. (EMPEROR-Preserved.)
5. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–1098. (DELIVER.)
6. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. (DAPA-HF.)
7. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. (DAPA-CKD.)
8. Abdul-Ghani M, DeFronzo RA, Del Prato S, et al. Cardiovascular disease and type 2 diabetes: Has the dawn of a new era arrived? Diabetes Care. 2017;40(7):813–820. (Mechanisms underlying CV protection.)